Zusammenfassung
Die Einführung der ACE-Hemmer in die klinische Medizin ist ein Beispiel für eine zielgerichtete pharmakologische Entwicklung und stellt ein völlig neues, pathophysiologisch sinnvolles Prinzip für die Behandlung der arteriellen Hypertonie und der Herzinsuffizienz dar [1, 2]. Aufgrund der Erfahrungen, die in den vergangenen 12 Jahren mit dieser Therapie in der praktischen Medizin gewonnen wurden, werden ACE-Hemmer heute neben Kalziumantagonisten, β-Rezeptorenblockern, Diuretika und postsynaptischen α-Blockern zur Initialbehandlung von hypertensiven Patienten eingesetzt [3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Cushman DW, Cheung HS, Sabo EF, Ondetti MA (1977) Design of potent competitive inhibitors of angiotensin-converting enzyme. Biochemistry 16: 5484–5487
Cushman DW, Cheung HS, Sabo EF, Ondetti MA (1978) Design of new antihypertensive drugs: Potent and specific inhibitors of angiotensin-converting enzyme. Progr Cardiovase Dis 21: 176–180
Joint National Committee (1988) The 1988 report of the Joint National Committee for the detection, evaluation, and treatment of high blood pressure. Arch Intern Med 148: 1023–1038
Stumpe KO, Overlack A, Kolloch R, Schreyer S (1982) Longterm efficacy of angiotensin-converting enzyme inhibition with captopril in mild—moderate essential hypertension. Br J Clin Pharmacol 14: 121S - 126S
Imai Y, Abe K, Seino M, Haruyama T, Tajiama J, Sato M, Goto T et al. (1982) Attenuation of pressor response to norepinephrine and vasopressin by captopril in human subjects. Hypertension 4: 444–450
Warren SE, O’Connor DT, Cohen IM (1983) Autonomic and baroreflex function after captopril in hypertension. Am Heart 105: 1002–1007
Cody RJ jr, Franklin KW, Laragh JH (1982) Postural hypertension during tilt with chronic captopril and diuretic therapy of severe congestive heart failure. Am Heart J 103: 480–486
Anderson S, Rennke HG, Brenner BM (1986) Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal diseases associated with systemic hypertension in the rat. J Clin Invest 77: 1993–2000
Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y (1985) Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313: 1617–1620
Asmar RG, Pannier B, Santoni J-Ph, Laurent S, London GM, Levy BI, Safar ME (1988) Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 78: 941–948
Fröhlich ED, Cooper RA, Lewis EJ (1984) Review of the overall experience of captopril in hypertension. Arch Intern Med 144: 1441–1444
Ventura HO, Fröhlich ED, Messerli FH, Kobrin I, Kardon MB (1985) Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. Am J Cardiol 55: 1023–1026
Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I, Fröhlich ED (1984) Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 2: 57–61
Christensen KL, Jespersen LT, Mulvany MJ (1989) Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure. J Hypertension 7: 83–90
Levy BI, Michel JB, Salzmann JL, Devissaguet M, Camilleri JP, Safar ME (1989) Effects of chronic converting enzyme inhibition on the structure and function of large arteries in the rat. Clin Exp (Theory and Practice) A 11 (Suppl 2): 487–498
Ferrannini E, Buzzigoli G, Bonadonna R (1987) Insulin resistance in essential hypertension. N Engl J Med 317: 350–357
Pollare T, Lithell H, Berne C (1989) A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321: 868–873
Pollare T, Lithell H, Selinus I, Berne C (1989) Sensitivity to insulin during treatment with atenolol and metroprolol: a randomized, double-blind-study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 298: 1152–1157
MacMahon SW, Cutler JA, Furberg CD, Payne GH (1989) The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis 29 (Suppl 1): 99
Ames RP, Hill P (1976) Increase in serum lipids during treatment of hypertension with chlorthalidone. Lancet 1: 721
Sesoko S, Keneko Y (1985) Cough associated with use of captopril. Arch Intern Med 145: 15–24
Sakaguchi K, Chai SY, Jackson B, Johnston CJ, Mendelsohn FAO (1988) Inhibition of tissue angiotensin converting enzyme. Hypertension 11 /3: 230–238
Elliot WJ, Murphy MB, Karp R (1988) Long-term preservation of renal function in hypertensive cardiac transplant recipients with enalapril and a diuretic. (Proceedings; International Symposium on ACE Inhibition, London; Abstract F068 )
Kingma JH, Van Gilst WH, Graeff P de, Louwerenburg HW, Six AJ, Wesseling H (1988) Captopril during thrombolysis in myocardial infarction: Feasibility, tolerance and beneficial neurohumoral effects. (Proceedings; International Symposium on ACE Inhibition, London; Abstract F182 )
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Stumpe, K.O. (1990). Stellung der ACE-Hemmer bei der Behandlung kardiovaskulärer Erkrankungen — Gegenwart und Zukunft. In: Stumpe, K.O., Klaus, D. (eds) Blutdrucksenkung heute — Korrektur von Struktur und Funktion der Arterie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85813-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-85813-0_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53417-4
Online ISBN: 978-3-642-85813-0
eBook Packages: Springer Book Archive